Biblio

Export 362 results:
Author [ Title(Desc)] Type Year
Filters: First Letter Of Last Name is E  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
K. Javanshiri, Waldö, M. Landqvist, Friberg, N., Sjövall, F., Wickerström, K., Haglund, M., and Englund, E., “Atherosclerosis, Hypertension, and Diabetes in Alzheimer's Disease, Vascular Dementia, and Mixed Dementia: Prevalence and Presentation.”, J Alzheimers Dis, vol. 65, no. 4, pp. 1247-1258, 2018.
S. Eketjäll, Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J., Haeberlein, S. Budd, Kugler, A. R., Alexander, R. C., and Cebers, G., “AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics.”, J Alzheimers Dis, vol. 50, no. 4, pp. 1109-23, 2016.
G. Cebers, Alexander, R. C., Haeberlein, S. Budd, Han, D., Goldwater, R., Ereshefsky, L., Olsson, T., Ye, N., Rosen, L., Russell, M., Maltby, J., Eketjäll, S., and Kugler, A. R., “AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1039-1053, 2017.
G. Cebers, Alexander, R. C., Haeberlein, S. Budd, Han, D., Goldwater, R., Ereshefsky, L., Olsson, T., Ye, N., Rosen, L., Russell, M., Maltby, J., Eketjäll, S., and Kugler, A. R., “AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1039-1053, 2017.
B
M. Timmers, Barão, S., Van Broeck, B., Tesseur, I., Slemmon, J., de Waepenaert, K., Bogert, J., Shaw, L. M., Engelborghs, S., Moechars, D., Mercken, M., Van Nueten, L., Tritsmans, L., De Strooper, B., and Streffer, J. Rolf, “BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants.”, J Alzheimers Dis, vol. 56, no. 4, pp. 1437-1449, 2017.
E. Schwertner, Pereira, J. B., Xu, H., Secnik, J., Winblad, B., Eriksdotter, M., Nägga, K., and Religa, D., “Behavioral and Psychological Symptoms of Dementia in Different Dementia Disorders: A Large-Scale Study of 10,000 Individuals.”, J Alzheimers Dis, vol. 87, no. 3, pp. 1307-1318, 2022.
A. D. Dekker, Sacco, S., Carfi, A., Benejam, B., Vermeiren, Y., Beugelsdijk, G., Schippers, M., Hassefras, L., Eleveld, J., Grefelman, S., Fopma, R., Bomer-Veenboer, M., Boti, M., G Oosterling, D. E., Scholten, E., Tollenaere, M., Checkley, L., Strydom, A., Van Goethem, G., Onder, G., Blesa, R., Eulenburg, C. Zu, Coppus, A. M. W., Rebillat, A. - S., Fortea, J., and De Deyn, P. P., “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.”, J Alzheimers Dis, vol. 63, no. 2, pp. 797-819, 2018.
A. D. Dekker, Sacco, S., Carfi, A., Benejam, B., Vermeiren, Y., Beugelsdijk, G., Schippers, M., Hassefras, L., Eleveld, J., Grefelman, S., Fopma, R., Bomer-Veenboer, M., Boti, M., G Oosterling, D. E., Scholten, E., Tollenaere, M., Checkley, L., Strydom, A., Van Goethem, G., Onder, G., Blesa, R., Eulenburg, C. Zu, Coppus, A. M. W., Rebillat, A. - S., Fortea, J., and De Deyn, P. P., “The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.”, J Alzheimers Dis, vol. 63, no. 2, pp. 797-819, 2018.
D. A. Levine, Gross, A. L., Briceño, E. M., Tilton, N., Whitney, R., Han, D., Giordani, B. J., Sussman, J. B., Hayward, R. A., Burke, J. F., Elkind, M. S. V., Moran, A. E., Tom, S., Gottesman, R. F., Gaskin, D. J., Sidney, S., Yaffe, K., Sacco, R. L., Heckbert, S. R., Hughes, T. M., Lopez, O. L., Allen, N. Bai, and Galecki, A. T., “Blood Pressure and Later-Life Cognition in Hispanic and White Adults (BP-COG): A Pooled Cohort Analysis of ARIC, CARDIA, CHS, FOS, MESA, and NOMAS.”, J Alzheimers Dis, vol. 89, no. 3, pp. 1103-1117, 2022.
D. L. Ebel, Torkilsen, C. G., and Ostrowski, T. D., “Blunted Respiratory Responses in the Streptozotocin-Induced Alzheimer's Disease Rat Model.”, J Alzheimers Dis, vol. 56, no. 3, pp. 1197-1211, 2017.
A. G. Senejani, Maghsoudlou, J., El-Zohiry, D., Gaur, G., Wawrzeniak, K., Caravaglia, C., Khatri, V. A., MacDonald, A., and Sapi, E., “Borrelia burgdorferi Co-Localizing with Amyloid Markers in Alzheimer's Disease Brain Tissues.”, J Alzheimers Dis, vol. 85, no. 2, pp. 889-903, 2021.
C
C. Lachner, Day, G. S., Camsari, G. Balci, Kouri, N., Ertekin-Taner, N., Boeve, B. F., Labuzan, S. A., Lucas, J. A., E Thompson, A., Siddiqui, H., Crook, J. E., Cabrera-Rodriguez, J. N., Josephs, K. A., Petersen, R. C., Dickson, D. W., R Reichard, R., Mielke, M. M., Knopman, D. S., Graff-Radford, N. R., and Murray, M. E., “Cancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old.”, J Alzheimers Dis, vol. 90, no. 1, pp. 405-417, 2022.
K. J. Edmunds, Driscoll, I., Hagen, E. W., Barnet, J. H., Ravelo, L. A., Plante, D. T., Gaitán, J. M., Lose, S. R., Motovylyak, A., Bendlin, B. B., Okonkwo, O. C., and Peppard, P. E., “Cardiorespiratory Fitness Attenuates the Deleterious Effects of Sleep Apnea on Cerebral Structure and Perfusion in the Wisconsin Sleep Cohort Study.”, J Alzheimers Dis, vol. 95, no. 2, pp. 427-435, 2023.
E. Mariani, Chattat, R., Vernooij-Dassen, M., Koopmans, R., and Engels, Y., “Care Plan Improvement in Nursing Homes: An Integrative Review.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1621-1638, 2017.
M. A. Burguillos, Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L., and Joseph, B., “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
M. M. Vasavada, Martinez, B., Wang, J., Eslinger, P. J., Gill, D. J., Sun, X., Karunanayaka, P., and Yang, Q. X., “Central Olfactory Dysfunction in Alzheimer's Disease and Mild Cognitive Impairment: A Functional MRI Study.”, J Alzheimers Dis, vol. 59, no. 1, pp. 359-368, 2017.
I. van Steenoven, Aarsland, D., Weintraub, D., Londos, E., Blanc, F., van der Flier, W. M., Teunissen, C. E., Mollenhauer, B., Fladby, T., Kramberger, M. G., Bonanni, L., and Lemstra, A. W., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort.”, J Alzheimers Dis, vol. 54, no. 1, pp. 287-95, 2016.
E. Niemantsverdriet, Ottoy, J., Somers, C., De Roeck, E., Struyfs, H., Soetewey, F., Verhaeghe, J., Van den Bossche, T., Van Mossevelde, S., Goeman, J., De Deyn, P. Paul, Mariën, P., Versijpt, J., Sleegers, K., Van Broeckhoven, C., Wyffels, L., Albert, A., Ceyssens, S., Stroobants, S., Staelens, S., Bjerke, M., and Engelborghs, S., “The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.”, J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
P. Lewczuk, Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. Luis, Eusebi, P., Kornhuber, J., Morris, J. C., and Fagan, A. M., “Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease.”, J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
G. P. Paraskevas, Kasselimis, D., Kourtidou, E., Constantinides, V., Bougea, A., Potagas, C., Evdokimidis, I., and Kapaki, E., “Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia.”, J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., “Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team.”, J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
M. Bjerke and Engelborghs, S., “Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis.”, J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
L. Parnetti and Eusebi, P., “Cerebrospinal Fluid Biomarkers in Alzheimer's Disease: An Invaluable Tool for Clinical Diagnosis and Trial Enrichment.”, J Alzheimers Dis, vol. 64, no. s1, pp. S281-S287, 2018.
S. Lista, Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., Cavedo, E., Santos, A. Melo Dos, Epelbaum, S., Lamari, F., Dubois, B., Nisticò, R., Floris, R., Garaci, F., and Hampel, H., “Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 59, no. 4, pp. 1327-1334, 2017.
A. De Vos, Struyfs, H., Jacobs, D., Fransen, E., Klewansky, T., De Roeck, E., Robberecht, C., Van Broeckhoven, C., Duyckaerts, C., Engelborghs, S., and Vanmechelen, E., “The Cerebrospinal Fluid Neurogranin/BACE1 Ratio is a Potential Correlate of Cognitive Decline in Alzheimer's Disease.”, J Alzheimers Dis, vol. 53, no. 4, pp. 1523-38, 2016.

Pages